



*Technology Transition Workshop*

# **High Throughput Analysis of Amplified Nucleic Acids with Mass Spectrometry: The Ibis Platform**

Steven A. Hofstadler, Ph.D.

Ibis Biosciences, Inc.



# Outline

- The challenge of broad pathogen detection
- The Ibis approach
  - Principle of operation
- Bacterial detection and strain typing
  - Group A strep - direct throat swab analysis
- Viral detection and strain typing
  - Influenza
    - Pan-influenza detection and strain typing
- Integrated platform



*Technology Transition Workshop*

# **The Pathogen Detection Arena**

- Biological weapons defense is not just about anthrax
- Food safety is not just about E. coli 0157
- Hospital associated infections are not just due to Staph. aureus



# The Pathogen Detection Arena

- There are *numerous* naturally occurring infectious diseases
- Over 1000 agents known to infect humans\*
  - 217 virus species
  - 538 bacterial species
  - 307 fungi
  - 66 parasitic protozoa
- Additional plant and animal pathogens not counted
- Numerous strain variations
- Potential bio-engineered organisms

*\*Taylor et al. Phil. Trans. R. Soc. Lond. B (2001) 356, 983-989*

# Mainstream Bioagent Detection

## Today

- Culture techniques
  - Detects a subset of all pathogens
  - Can take multiple days (weeks)
- Single agent nucleic acid tests
  - One test for each agent (smallpox, anthrax, plague, etc.)
  - Need too many tests
  - Fail to detect newly emergent pathogens
- There is currently no good method to detect organisms that have never been seen before

























IMAGE COURTESY OF STEVEN A. HOFSTADLER, PH.D.

# Bacterial Threat Symbols

## Microbial Rosetta Stone Database

- |  |   |
|--|---|
|  <i>NIAID Category A Priority Pathogen</i>    |  <i>Globally Important Human Pathogen</i>  |
|  <i>NIAID Category B Priority Pathogen</i>    |  <i>Medically Important Human Pathogen</i> |
|  <i>NIAID Category C Priority Pathogen</i>    |  <i>Important Animal Pathogen</i>          |
|  <i>HHS Select Agent</i>                      |  <i>Important Plant Pathogen</i>           |
|  <i>USDA High Consequence Animal Pathogen</i> |  <i>High Potential For Bioengineering</i>  |
|  <i>USDA High Consequence Plant Pathogen</i>  |  <i>Zoonotic Agent</i>                     |
|  <i>Validated Biological Weapon</i>         |  <i>Toxin</i>                              |
|  <i>Potential Biological Weapon</i>         |  <i>CDC Notifiable Agent</i>              |
|  <i>Validated Biocrime Agent</i>            |  <i>Principal Foodborne Pathogen</i>     |
|  |  <i>Emerging Infectious Agent</i>        |

# Bacteria





# **Why Detect and/or Type Microorganisms via Nucleic Acids?**

- All living things rely on DNA and/or RNA to propagate
  - All infectious agents\* contain DNA and/or RNA
  - Bacteria, viruses, fungi, protozoa
- DNA and RNA are unique among biomarkers in that they can be amplified (e.g. PCR, WGA, NASBA, etc.)
  - From trace amounts of sample
  - From highly degraded samples
  - From samples in complex backgrounds
- **NO CULTURE REQUIRED**

*\* Except those nasty prions!*









# **Why Detect and/or Type Microorganisms via Nucleic Acids?**

- Some genetic differences do not result in phenotypic differences
  - e.g. rRNA, VNTRs, SNPs
- Range of specificity can be “tuned” for different applications
  - “Name That Bug”: broad range primers
  - “Genotype/Strain - Type That Bug”: species specific primers
  - “Profile That Bug”: drug resistance, virulence markers, etc.

# Amplified Nucleic Acids

- Sequencing
  - “Gold Standard”
- Fluorescent intercalating dye
- Hybridization
  - Specific probe with FRET pair
- DNA microarray
- Melting profiles
- Electrophoresis
  - Slab gels
  - Capillary gel electrophoresis
- **WHAT ABOUT MASS?**





*Technology Transition Workshop*

# ***Identification and Strain Typing of Bacterial and Viral Pathogens Using High Performance Mass Spectrometry: The Ibis Concept***

Defense Advanced Research Projects (DARPA)


Centers for Disease Control (CDC)

National Institute of Allergy and Infectious Diseases (NIAID)


Department of Homeland Security (DHS)

# The Ibis Approach to Pathogen ID and Strain-Typing


- STEP 1** Identify genomic regions for identification:  
Variable DNA sequences flanked by conserved sequences




- STEP 2** Amplify nucleic acids to measure:  
Use broad-range, unbiased PCR primers



- STEP 3** Measure nucleic acid:  
ESI-TOF




- STEP 4** Identify the organisms:  
Base-composition fingerprints



# Broad Range Priming in Bacteria

STEP  
**1**

Primers bind to conserved  
regions present in ALL  
(or groups of) bacteria




Region varies in different  
kinds of bacteria  $\Rightarrow$

$$\Delta [A_w G_x C_y T_z]$$

# The Polymerase Chain Reaction (PCR)

**STEP**  
**2**





- Performed using primers designed for broad coverage
- PCR cycling conditions tolerate mismatches on initial cycles
- All primer pairs designed to work under identical PCR conditions
- Each well contains an internal calibrant
- Generally don't multiplex broad range primers (e.g. 16S and 23S rDNA)
- Multiplexing of more specific primers common (e.g. strain typing, drug resistance, virulence)

**STEP**  
**3**

Measure nucleic acid:

Electrospray Ionization (ESI)

Time-of-flight (TOF) Mass Spectrometry



# Masses to Base Composition

STEP

4

© Microsoft Media Elements



Penny = 2.500 g  
Nickel = 3.950 g  
Dime = 2.268 g  
Quarter = 5.670 g

© Microsoft Media Elements




**Weight = 4.6 grams**  
**∴ 2 dimes**



A = 313.0576 amu  
G = 329.0526 amu  
C = 289.0464 amu  
T = 304.0461 amu

© Microsoft Media Elements



**MW = 32,588.90 amu**  
**∴ A28 G29 C25 T24**

**Requires 25 ppm**  
**mass measurement error**

**Math takes into account**  
**Watson-Crick base pairing**

**Mass spectrum** IMAGE COURTESY OF STEVEN A. HOFSTADLER, PH.D.




### Primer 356 (RplB) Expected Products

Identify the organisms:

STEP  
**4**

Base-composition  
fingerprints





# **Broad Pathogen Detection**

**Instead of asking; “Is pathogen X in my sample?”, we ask:  
“Which pathogen, or pathogens, are in my sample?”**

# **Group A Streptococcus (GAS) Outbreaks in Military Settings**


- Outbreaks of Group A strep at MCRC 2002/2003
  - Highly virulent strain
  - One death, 160 hospitalized
  - Training activities suspended
- Initial analysis of post-culture samples
  - 80 samples sent from NHRC, Dr. Kevin Russell, December 20, 2002
  - “Hijacked” some BW air surveillance plates
- Follow up surveillance at multiple military bases
- Direct analysis of throat swabs without culture



# Technology Transition Workshop

## Primer 17 (a 23S primer)

### Observed Products (from culture)



**All primers of all samples consistent with *S. pyogenes***



# Direct Analysis of Throat Swab\*

\*Repeat swab positive on culture for *Streptococcus pyogenes*



## Technology Transition Workshop

# Multi-primer Triangulation

Organism	Cumulative Estimate of Genomes/Swab	Relative Abundances
<i>Haemophilus influenzae</i>	7.38E+05	1.00
<i>Neisseria meningitidis</i>	3.77E+05	0.51
<i>Streptococcus pyogenes</i>	1.89E+05	0.26

# Technology Transition Workshop

## Haemophilus influenzae, Neisseria meningitidis, Streptococcus pyogenes (Ratio 4/2/1, 1.5 X 10<sup>6</sup> genomes/swab)

Primer #1	Mass	Base Count
Blue	18234.970	A <sub>12</sub> G <sub>17</sub> C <sub>17</sub> T <sub>13</sub>
Blue	17948.926	A <sub>14</sub> G <sub>14</sub> C <sub>12</sub> T <sub>18</sub>
Blue	18610.017	A <sub>11</sub> G <sub>19</sub> C <sub>15</sub> T <sub>15</sub>
Blue	17936.912	A <sub>11</sub> G <sub>17</sub> C <sub>16</sub> T <sub>14</sub>
Blue	18877.118	A <sub>18</sub> G <sub>15</sub> C <sub>15</sub> T <sub>13</sub>





IMAGE COURTESY OF CHRISTIAN MASSIRE, PH.D.

# Conclusions of Pneumonia Study\*

- **Primary pathogen**
  - *Streptococcus pyogenes* (GAS)
  - Known virulent strain
- **Secondary pathogens**
  - *Haemophilus influenzae*
  - *Neisseria meningitidis*
- **5 other military facilities**
  - Determined these sites had a mixture of strain types
- **Throughput**
  - >200/samples per day





*Technology Transition Workshop*

# **Virus Identification and Typing**

# Technology Transition Workshop

# Viral Coverage





IMAGE COURTESY OF CHRISTIAN MASSIRE, PH.D.





*Technology Transition Workshop*  
**Influenza Virus Surveillance:**  
**Project Collaborators**

***CMDR Kevin Russell M.D., Naval Health Research Center,  
San Diego, CA***

***Kirsten St.George, MAppSc, PhD, New York State  
Department of Health, Slingerlands, NY***


***Charlotte Gaydos, Dr.P.H. and Rich Rothman, M.D.  
Johns Hopkins University, Baltimore, MD***

***Stan Lemon M.D. , University of Texas Medical Branch,  
Galveston, TX***

***Wendy Sessions. M, SV (ASCP), Texas Department of  
State Health Services***

***Dave Stallknecht and Ginger Goekjian, College of  
Veterinary Medicine, University of Georgia***

# Ibis T5000™ Influenza Virus Assay



# Technology Transition Workshop

## Pan-influenza Primer Polymerase PB1 Primer

Human and Swine H1N1, H2N2, H3N2

Canine, Equine H3N8

Human, Avian H5N1


Other Avian, Swine


Influenza B and C



IMAGE COURTESY OF STEVEN A. HOFSTADLER, PH.D.

# Pan-influenza Primer Polymerase PB1 Primer PP2798 - Base Composition






## Conclusion

**Samples 1 & 3: Influenza A virus  
(H3N2: A/New York/././2003)**

**Samples 2 & 4: Influenza B virus**



Organism	Sample Score	Basecount	Peak1 Mass	Peak1 Abundance	Peak1 Fit Error	Peak2 Mass	Peak2 Abundance
Influenza A virus A/NEW YORK/14/2003(H3N2)	0.96539	A26G20C23T32	31051.6 31364.1	3030.0 396.0	0.0 0.0	31225.7 3440.0	3440.0
Influenza A virus A/NEW YORK/15/2003(H3N2)	0.96539	A26G20C23T32	31051.6 31364.1	3030.0 396.0	0.0 0.0	31225.7 3440.0	3440.0
Influenza A virus A/NEW YORK/16/2003(H3N2)	0.96539	A26G20C23T32	31051.6 31364.1	3030.0 396.0	0.0 0.0	31225.7 3440.0	3440.0
<b>Influenza A virus A/NEW YORK/21/2003(H3N2)</b>	<b>0.96539</b>	<b>A26G20C23T32</b>	<b>31051.6 31364.1</b>	<b>3030.0 396.0</b>	<b>0.0 0.0</b>	<b>31225.7 3440.0</b>	<b>3440.0</b>
Influenza A virus A/NEW YORK/22/2003(H3N2)	0.96539	A26G20C23T32	31051.6 31364.1	3030.0 396.0	0.0 0.0	31225.7 3440.0	3440.0
Influenza A virus A/NEW YORK/24/2003(H3N2)	0.96539	A26G20C23T32	31051.6 31364.1	3030.0 396.0	0.0 0.0	31225.7 3440.0	3440.0
Influenza A virus A/NEW YORK/25/2003(H3N2)	0.96539	A26G20C23T32	31051.6 31364.1	3030.0 396.0	0.0 0.0	31225.7 3440.0	3440.0
Influenza A virus A/NEW YORK/26/2003(H3N2)	0.96539	A26G20C23T32	31051.6 31364.1	3030.0 396.0	0.0 0.0	31225.7 3440.0	3440.0
Influenza A virus A/NEW YORK/268/2003(H3N2)	0.96539	A26G20C23T32	31051.6 31364.1	3030.0 396.0	0.0 0.0	31225.7 3440.0	3440.0
Influenza A virus A/NEW YORK/27/2003(H3N2)	0.96539	A26G20C23T32	31051.6	3030.0	0.0	31225.7	3440.0





# Technology Transition Workshop

## Human Influenza Trial - Blinded Samples

Source	Location	Collection Dates	Sample type	No. of Samples
Naval Health Research Center	MCRD, San Diego Ft. Leonard Wood, Ft. Sill, Ft. Benning, Lackland AFB	1999-2005	Throat swabs, nasal swabs, nasal washes	317
Johns Hopkins University Medical Center	Baltimore, MD	2003-2005	Nasal aspirates	229
NY State Dept. of Health	Throughout NY	1999-2005	Nasal aspirates, BAL, tracheal aspirates, throat swabs	100
TX State Dept. of Health	Throughout TX	2005-2006	Throat swabs, nasal washes	10
<b>Total</b>				<b>656</b>

**–Correctly identified all Influenza A types**


➤ 149 H3N2

➤ 34 H1N1

**–67 Influenza B**

Influenza	
<b>Sensitivity</b>	96.8%
<b>Specificity</b>	97.5%
<b>PPV</b>	96.0%
<b>NPV</b>	98.0%

# Detection of Mixed Infections





Technology Transition Workshop


# Validation Study

## Test Isolates from Diverse Sources

- 24 human influenza isolates
  - 18 influenza A
  - 6 influenza B
- 63 avian influenza isolates
  - 16 different avian species
    - chicken, duck, goose, egret, teal, ....
  - 28 distinct H/N types
    - **29 HIGHLY PATHOGENIC H5N1 isolates**
  - 8 worldwide geographic locations
    - North America, Africa, Asia
- 4 swine influenza isolates
- 1 equine influenza isolate

# Avian Flu Detection:

## No Change in Assay or Primers





# Technology Transition Workshop

## Avian Influenza Virus Detection:

### University of Georgia Samples

#### 24 avian influenza virus isolates collected over a six-year period

- Different host species: mallard, seagull, teal,...
- Different combinations of H and N subtypes: H12N4, H3N8...

SCWDS ID#	Serotype	Species	Location	Date
AI00-1412	H6N1	REKN	Bower's Beach, DE	5/25/00
AI00-1794	H12N4	RUTU	Bower's Beach, DE	5/20/96
AI00-2150	H12N5	RUTU	Villas, NJ	5/15/96
AI00-629	H7N9	RUTU	Port Mahon, DE	5/19/96
AI02-262	H2N4	RUTU	Mispillion Harbor, DE	5/22/98
AI02-690	H2N9	RUTU	Reed's Beach, NJ	5/22/98
AI03-128	H9N7	RUTU	Reed's Beach, NJ	5/20/99
AI03-128	H9N7	RUTU	Reed's Beach, NJ	5/20/99
AI03-755	H9N5	RUTU	Mispillion Harbor, DE	5/20/99
AI04-127	H10N7	RUTU	Bower's Beach, DE	5/19/00
AI05-415	H3N8	RUTU	Fortescue Beach, NJ	5/21/01
AI05-415	H3N8	RUTU	Fortescue Beach, NJ	5/21/01
AI05-669	H11N8	RUTU	Reed's Beach, NJ	5/25/01
AI05-784	H11N6	RUTU	Reed's Beach, NJ	5/25/01
MN00-283	H5N2	MALL	Thief Lake, MN	9/10/96
MN00-382	H5N3	MALL	Thief Lake, MN	9/10/96
MN98-115	H4N8	MALL	Roseau Co., MN	09/ /1998
MN98-115	H4N8	MALL	Roseau Co., MN	09/ /1998
MN98-66	H6N5	MALL	Roseau Co., MN	09/ /1998
MN99-160	H4N6	MALL	Roseau Co., MN	/ /1999
MN99-17	H7N7	MALL	Roseau Co., MN	/ /1999
NC6412-009	H10N7	MALL	JM Futch, NC	12/20/00
NC675-075	H3N2	ABDU	Mattamuskeet, NC	12/21/00
TX01-32	H8N4	CITE	Brazoria Co., TX	2/11/97
TX01-7	H8N4	AGWT	Brazoria Co., TX	2/11/97
TX02-27	H1N4	BWTE	Brazoria Co., TX	2/18/98
TX02-75	H1N3	BWTE	Brazoria Co., TX	2/18/98



# Conclusions

- By “weighing” DNA with mass spectrometry, unambiguous base compositions can be derived
  - Remember coins and scale analogy!
- Base compositions derived from broad range primers can be used to triangulate to microbial identification
- Ibis platform enables broad range bacterial and viral detection
  - Broad bacterial coverage using broad range primers
    - **Example: Direct analysis of throat swabs**
  - All influenza (human and avian) in same assay
    - **Example: Human clinical specimens and avian isolates**
- Respiratory Virus Surveillance Assay provides a single test platform for 6 families of RNA and DNA respiratory viruses
- Demonstrated for bacteria and viruses without culture
  - Also applicable to fungi, protozoa, and humans (not shown)

**Instead of asking; “Is pathogen X in my sample?”, Ibis approach asks: “Which pathogen(s) are in my sample.**



*Technology Transition Workshop*




## **Hardware Overview**



# System History




**TIGER 1.0**  
**2000-2003**



**TIGER 2.0**  
**2003**

© 2009 Ibis Biosciences, Inc.



**TIGER 2.0'**  
**2004-2006**

© 2009 Ibis Biosciences, Inc.



**2006-2009**

© 2009 Ibis Biosciences, Inc.



**Ibis T6000**  
**2009-**



© 2009 Ibis Biosciences, Inc.

**TIGER 1.0**

# Instrument Formerly Known as TIGER 2.0' - Configuration

- Primary mission is pathogen characterization & bioforensics
- Spatially isolated enclosures
  - A Deck: genome isolation and PCR setup
  - B Deck: PCR, desalt, ESI-TOF, GenX
- Magnetic bead desalting
- Technician transports samples from A Deck to B Deck
- Footprint (A + B) = 54 ft<sup>2</sup>





# **Change in Instrument Format**

- Rationale – Motivated by discussions with Johns Hopkins and CDC
  - Space is premium in hospital/diagnostic labs
  - Much of “A Deck” function already present in many labs
  - Many different groups/applications use different sample prep protocols
    - CDC core lab model
  - Non-integrated “A Deck” components can be used for other lab functions
  - Lower cost for hardware
- Deployments:
  - CDC in Atlanta, GA
  - FBI in Quantico, VA (2)




# **Deployed Systems (T5000) - FBI**

- Federal Bureau of Investigation
- Two Ibis T5000™ systems installed in DNA Unit II
- mtDNA forensics analysis
  - Replaces existing sequence-based methods(details to follow)
    - Cost
    - Throughput
    - Heteroplasmy
    - Mixtures
- FBI and Ibis finishing validation package


# Ibis T5000™

- Amplicon purification
- Automated ESI-TOF analysis
  - Robotic arm moves plates for unattended operation
- Data analysis
- Other functions performed off-line
  - DNA/RNA extraction
  - Plate set up into pre-kitted plates
  - PCR
- High throughput
  - 1 well/minute
  - 46 sec spray
  - 14 sec rinse



# Ibis T5000™ Components

- Bruker Daltonics micrOTOF™
- Thermo CRS robotic arm
  - 3 x 15 plate storage
- LEAP autosampler
- Custom fluidics module
  - Programmable Cavo® pumps
- Heat sealer
- Ibis magnetic bead cleanup module
  - Modified LEAP
  - 8-channel head
  - Shaker
  - Magnetic plate
- Bar code reader
- Computers





# **Ibis T6000™**

- Key features
  - Remove dependence on complex, high cost 3<sup>rd</sup> party components
  - Compatibility with existing PCR plates
  - Compatibility with existing cleanup chemistry
  - Accommodate priority “stat” sample
  - Bottom up design with IVD market in mind
    - Rigorously controlled design criteria from the start
  - Support 30 second/well throughput
  - Design and build prototypes such that clinical device manufacturer can build system under FDA-compliant design/manufacturing control



# Ibis T6000™ Design

- Same magnetic bead chemistry as T5000
- Spin cuvettes (22) aligned in carousel
- Magnetic beads aliquoted from bead reservoir
  - No mag bead plate
  - No elution plate
- No robotic arms, heat sealers, LEAPS, etc
- Accommodate “stat” sample priority interrupt





## *Technology Transition Workshop*

# **Contact Information:**

Steven A. Hofstadler, Ph.D.

Ibis Biosciences, Inc.

Email: [shofstadler@ibisbio.com](mailto:shofstadler@ibisbio.com)